November 12th 2024
Elraglusib is undergoing investigation in an open-label, multicenter, phase 1/2 trial for the treatment of patients with Ewing sarcoma.
September 12th 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Clears SeCore CDx as Companion Diagnostic for Afami-cel in Synovial Sarcoma
August 7th 2024The FDA has granted 510(k) clearance to the SeCore™ CDx HLA A sequencing system as companion diagnostic for afamitresgene autoleucel in synovial sarcoma, paving the way for a first-of-its-kind solid tumor therapy.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments
July 19th 2023For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
Read More
FDA Places Partial Clinical Hold on Study of FHD-609 in Synovial Sarcoma
April 25th 2023A patient treated with the second highest dose level of FHD-609 had a grade 4 adverse event. Enrollment in the study of the agent in patients with synovial sarcoma or SMARCB-1 deleted tumors has been halted.
Read More
Link Between pCR and Improved Survival for Patients With Soft Tissue Sarcoma
April 4th 2023Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.
Read More
Taking on the Challenge to Develop New Therapies for Pediatric Solid Tumors
January 31st 2023Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
Read More
Bringing Targeted Agents from Clinical Trials to the Clinic for Patients With Uterine Sarcoma
December 23rd 2022In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.
Read More
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22nd 2022With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
Read More